Strategic fit Target large vascular device ecosystems and hospitals that historically partner with or acquire innovative PAD technologies, leveraging PQ Bypass’s Breakthrough Device status and CE mark capabilities to open collaboration or licensing discussions with leading medtech players.

Acquisition leverage Position PQ Bypass as an attractive acquisition target for larger firms seeking advanced minimally invasive solutions for long-segment PAD, highlighting prior acquisition by Endologix and the strong executive pedigree to accelerate due diligence and deal discussions.

Clinical momentum Emphasize proven clinical activity and regulatory milestones (Detour program, CE marks) to support outreach to clinical champions and KOLs at ambulatory surgical centers and academic centers for expedited trials, pilot programs, or surgeon education partnerships.

Expansion opportunities Propose joint development or co-marketing arrangements with established cardiovascular players to expand indication reach and regional commercialization, leveraging existing FDA Breakthrough Device designation to accelerate regulatory and reimbursement pathways.

Global channels Leverage Frost and Sullivan recognition and European technology award to open conversations with European distributors and regional medtech groups, aligning market access strategies with countries prioritizing minimally invasive PAD therapies and favorable reimbursement environments.